REHOVOT, Israel, Sept. 27 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today updated progress on a Phase II clinical trial for its proprietary development compound MTR107 (i.v. formulation of MTR104), a low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. Current study enrollment projects a completion date of December 2006.
This Phase II double blind clinical trial will evaluate the pharmacokinetic and pharmacodynamic effects of MTR107 in twelve patients with End Stage Renal Disease (ESRD).
Intradialytic hypotension (IDH) is the most common adverse event during routine hemodialysis. IDH has been reported in 15-25% of all hemodialysis treatment groups, with elderly patient groups reporting levels exceeding 95%. Many adverse hemodialysis events -- including headaches, lightheadedness, nausea, cramps, and seizures, are associated with IDH. All of these symptoms can cause patient morbidity. These complications may repeatedly interrupt dialysis sessions, resulting in insufficient uremia toxin removal. Interruptions due to IDH both increase the costs of the dialysis treatment sessions and long-term care of less healthy hemodialysis patients.
Meditor Pharmaceuticals Ltd. is an Israel-based pharmaceutical development company founded to develop and commercialize a class of small organic synthetic molecules with profound cardiovascular pharmacologic activity. The lead development compound is MTR104, a low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. Meditor's patent portfolio provides the company with a strong proprietary position in the U.S. and worldwide. For more information on the company and its drug development activities, please visit www.meditorpharma.com .
Meditor Pharmaceuticals Ltd. is continuing with the development of its lead compound while currently seeking offers from pharmaceutical manufacturers having the potential to develop, register and commercialize MTR107. For all inquiries please contact Michael Schultz, R.Ph., VCG & Associates, Inc. at 636-329-1452 or Dr. David Coffin-Beach at 416-725-3956.
Meditor Pharmaceuticals Ltd.
CONTACT: Michael Schultz, R.Ph., of VCG & Associates, Inc.,+1-636-329-1452; or Dr. David Coffin-Beach, +1-416-725-3956, both forMeditor Pharmaceuticals Ltd.